Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When Standard BioTools Inc.’s mass cytometry systems shape immunotherapy studies worldwide, even a single line in the 10-K can move markets. Investors often ask, “Where can I review Standard BioTools quarterly earnings report 10-Q filing?” or “How do I track Standard BioTools insider trading Form 4 transactions?” Those answers live inside dense SEC documents—finding them can drain hours.
Stock Titan turns that complexity into clarity. Our AI delivers Standard BioTools SEC filings explained simply, spotlighting revenue from proteomics instruments, R&D cash burn, and obligations tied to leased manufacturing sites. You’ll see each Standard BioTools annual report 10-K simplified and Standard BioTools 8-K material events explained within minutes of hitting EDGAR. Real-time alerts surface Standard BioTools Form 4 insider transactions real-time, ensuring you never miss meaningful Standard BioTools executive stock transactions Form 4. Need faster context? Every Standard BioTools earnings report filing analysis pairs key metrics with peer benchmarks for immediate comparison.
Whether you’re building a valuation model or evaluating management incentives, critical disclosures are one click away:
- Track Standard BioTools proxy statement executive compensation to understand leadership alignment
- Compare margins and backlog across each Standard BioTools quarterly earnings report 10-Q filing
- Receive alerts on emerging risks via Standard BioTools 8-K material events explained
Understanding Standard BioTools SEC documents with AI means spending less time scrolling and more time deciding. Every filing, every footnote—decoded and delivered in real time.
STANDARD BIOTOOLS INC. (LAB)11/24/2025, they bought 150,000 shares of common stock at a weighted average price of $1.4325 per share. On 11/25/2025, they bought an additional 7,550,000 shares at a weighted average price of $1.3031 per share.
Following these transactions, one indirect holding line shows 71,750,000 shares beneficially owned, with ownership attributed to Casdin Partners Master Fund, L.P. and related entities. The filing also reports 2,901,062 shares held directly by Eli Casdin and additional indirect holdings of 13,939,637 and 2,744,219 shares through other Casdin-managed funds, reflecting a sizable continuing stake in LAB.
Standard Biotools Inc. (LAB) reported an insider equity transaction by its President & CEO and director, Michael Egholm. On 11/20/2025, the company withheld 63,529 shares of common stock at $1.28 per share to cover tax withholding obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Egholm beneficially owned 5,617,837 shares of Standard Biotools common stock directly.
Standard Biotools Inc. (LAB) reported an insider equity transaction by its Chief Financial Officer on 11/20/2025. The Form 4 shows that 12,739 shares of common stock were withheld at a price of $1.28 per share to cover tax obligations arising from the vesting of restricted stock units previously granted on May 20, 2024 and March 21, 2025. After this tax withholding transaction, the reporting person beneficially owns 2,415,086 shares of Standard Biotools common stock, held directly.
Standard BioTools Inc. (LAB) executive Sean Mackay, SVP & Chief Business Officer, reported a routine equity transaction on Form 4. On 11/20/2025, 19,661 shares of common stock were withheld at a price of $1.28 per share, indicated by transaction code "F," to cover tax obligations arising from the vesting of previously granted restricted stock units. After this tax withholding, Mackay beneficially owns 779,835 shares of Standard BioTools common stock directly.
Standard BioTools Inc. (LAB) large shareholder and director-affiliated entities managed by Eli Casdin reported open-market purchases of common stock. On 11/18/2025, they bought 275,000 shares at a weighted average price of $1.2342, followed by 350,000 shares at $1.2826 on 11/19/2025 and 450,000 shares at $1.3028 on 11/20/2025.
After these transactions, one indirect holding line shows 64,050,000 shares of LAB common stock, with other lines reporting 2,901,062 shares directly and additional indirect positions of 13,939,637 and 2,744,219 shares. The filing explains that various Casdin funds hold these positions and that Eli Casdin and related entities may be deemed to beneficially own the securities through their advisory and general partner roles, while each reports ownership only to the extent of its economic interest.
Standard BioTools Inc. (LAB) reported insider open-market purchases of its common stock by Casdin-affiliated investment entities that are directors and 10% owners. On 11/13/2025, they bought 450,000 shares at a weighted average price of $1.2031 per share. On 11/14/2025, they bought another 250,000 shares at a weighted average price of $1.2392, and on 11/17/2025, they bought 225,000 shares at a weighted average price of $1.2248.
Following these transactions, one indirect position is shown as 62,975,000 shares, with additional direct and indirect holdings of 2,901,062, 13,939,637, and 2,744,219 shares reported for various Casdin-managed funds and Eli Casdin. The filing notes that prices are weighted averages over multiple trades within stated ranges and that the securities of several funds may be deemed beneficially owned by Casdin Capital entities and Eli Casdin.
Standard BioTools (LAB) reported insider open‑market purchases by entities affiliated with Eli Casdin. The filing lists four buys totaling 1,175,000 shares on 11/07 (225,000 at a weighted average
Following these transactions, the Master Fund’s indirectly beneficially owned balance is stated as 62,050,000 shares. Additional positions reported include 2,901,062 shares held directly by Eli Casdin, 13,939,637 shares indirectly by Casdin Private Growth Equity Fund II, L.P., and 2,744,219 shares indirectly by Casdin Private Growth Equity Fund, L.P. The form is filed by more than one reporting person and marks the reporting persons as a director and 10% owner.
Standard BioTools (LAB) reported Q3 2025 results. Revenue from continuing operations was $19.6 million, down from $22.1 million a year ago. Gross profit was $9.5 million. The company posted a net loss of $34.7 million, including a $31.7 million loss from continuing operations and a $3.0 million loss from discontinued operations.
Operating expenses rose, with selling, general and administrative at $26.6 million, research and development at $6.4 million, and restructuring charges of $9.4 million. Cash and cash equivalents were $129.4 million, with $65.5 million in short‑term and $19.5 million in long‑term U.S. Treasury investments.
The SomaScan Business is classified as held for sale and reported as discontinued operations. On June 22, 2025, the company agreed to sell this business to Illumina for up to $425 million, including $350 million in cash at closing and up to $75 million in earnouts. Closing is subject to customary conditions. Shares outstanding were 384,565,414 as of November 2, 2025.
Standard BioTools Inc. furnished an 8-K announcing it issued a press release with selected financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1.
Sections titled “Operational Restructuring” and “Full Year 2025 Revenue Outlook,” along with the forward-looking statement disclaimer, are furnished under Regulation FD. The information in Items 2.02 and 7.01, including Exhibit 99.1, is expressly furnished and not deemed filed under the Exchange Act.
FAQ
What is the current stock price of STANDARD BIOTOOLS (LAB)?
What is the market cap of STANDARD BIOTOOLS (LAB)?
